Teva Pharmaceutical Industries Ltd. later this year plans to roll out lamivudine and zidovudine tablets, an HIV medication.


Teva Pharmaceutical Industries, Combivir Tablets, lamivudine, zidovudine, HIV medication, ViiV Healthcare, Glaxo Group, FDA, Food and Drug Administration, Pharmaceutical






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Teva to launch Combivir generic

May 27th, 2011

JERUSALEM – Teva Pharmaceutical Industries Ltd. later this year plans to roll out lamivudine and zidovudine tablets, an HIV medication.

Israel-based Teva said Thursday that the Food and Drug Administration has granted approval for the company's abbreviated new drug application (ANDA) to market a generic version of ViiV Healthcare Co.'s Combivir Tablets.

Plans call for Teva's product to begin shipping in the fourth quarter 2011, as per the terms of a settlement agreement between Teva and Glaxo Group Ltd. and ViiV Healthcare.

The branded product has annual sales of approximately $315 million in the United States, based on IMS Health sales data provided by Teva.

Teva noted that as the first company to file an ANDA containing paragraph IV certification for these products, it is eligible for a 180-day period of marketing exclusivity.

Advertisement